Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02389933




Registration number
NCT02389933
Ethics application status
Date submitted
10/03/2015
Date registered
17/03/2015
Date last updated
15/02/2021

Titles & IDs
Public title
Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)
Scientific title
Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)
Secondary ID [1] 0 0
CLCZ696B2318M
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Heart Failure With Reduced Ejection Fraction (HF-rEF) 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Coronary heart disease
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Expanded Access
Description of intervention(s) / exposure
Treatment: Drugs - LCZ696

Treatment: Drugs: LCZ696
immediate release film coated tablet in 50 mg, 100 mg, 200 mg, and 400 mg strengths for oral administration.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes

Eligibility
Key inclusion criteria
Inclusion criteria

The patient(s) for whom the MPP is sought meets all of the following:

- Is suffering from a serious or life-threatening disease or condition

- Does not have access to a comparable or satisfactory alternative treatment (i.e.,
comparable or satisfactory treatment is not available or does not exist)

- Patient should be on optimized standard of care treatment, including treatment with
ARBs or ACEI, beta-blockers and MRA;

- Intolerance to evidence-based target doses should be documented by the treating
physician

- Meets any other relevant medical criteria for compassionate use of the investigational
product

Patients eligible for inclusion in this program have to fulfill all of the following
criteria:

1. Adult patients (but not younger than 18 year old) will be included, upon completion of
written informed consent before any assessment is performed.

2. Patients with a diagnosis of CHF NYHA class II-IV and reduced ejection fraction:

• LVEF = 35% at the time of screening for participation in the program (any local
measurement, made within the past 6 months using echocardiography, MUGA, CT scanning,
MRI or ventricular angiography is acceptable, provided there are no subsequent
measurement above 35%)

3. Patient had a hospitalization for HF within the last 12 months

4. Patients must be on an ACEI or an ARB at a stable dose for at least 4 weeks prior to
starting treatment with LCZ696

5. Patients must be treated with a ß-blocker, unless contraindicated or not tolerated, at
a stable dose for at least 4 weeks prior to starting treatment with LCZ696 (reason
should be documented for patients not on CHF target doses per local guidelines, or in
absence of that medication).

6. An aldosterone antagonist should also be considered in all patients, taking account of
renal function, serum potassium and tolerability. If given, the dose of aldosterone
antagonist should be optimized according to guideline recommendations and patient
tolerability, and should be stable for at least 4 weeks prior to starting treatment
with LCZ696
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria

Patients fulfilling any of the following criteria are not eligible for inclusion in this
program:

1. The patient is eligible for participation in any of the IMP's ongoing clinical trials

2. The patient has recently completed a clinical trial that has been terminated and other
options (e.g., trial extensions, amendments, etc.) are available to continue a similar
treatment.

3. The patient is being transferred from an ongoing clinical trial for which the patient
is still eligible for participation

4. History of hypersensitivity or allergy to LCZ696 or to any of its metabolites; to
drugs of similar chemical classes, ARBs, or NEP inhibitors; as well as known or
suspected contraindications to LCZ696

5. Use of other investigational drugs at the time of enrollment, or within 30 days or 5
half-lives of enrollment, whichever is longer

6. Previous history of intolerance to recommended target doses of ARBs

7. Known history of angioedema

8. Requirement of concomitant treatment with both ACEIs and ARBs

9. Current acute decompensated HF (exacerbation of chronic HF manifested by signs and
symptoms that may require intravenous therapy)

10. Symptomatic hypotension and/or a SBP less than 100 mm Hg over the last 4 weeks prior
to starting treatment with LCZ696

11. Estimated GFR below 30 mL/min/1.73m2 as measured by the simplified MDRD formula

12. Presence of bilateral renal artery stenosis

13. Serum potassium above 5.2 mmol/L during the week prior to starting treatment with
LCZ696

14. Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other
major CV surgery, percutaneous coronary intervention (PCI) or carotid angioplasty
within the 3 months prior to starting treatment with LCZ696

15. Coronary or carotid artery disease likely to require surgical or percutaneous
intervention within the 6 months after the schedule date to start treatment with
LCZ696

16. Implantation of a cardiac resynchronization therapy pacemaker (CRT-P) or a cardiac
resynchronization therapy defibrillator (CRT-D) or upgrading of an existing
conventional pacemaker or an implantable cardioverter defibrillator (ICD) to CRT
device within 3 months prior to starting treatment with LCZ696, or intent to implant
such a device.

Also, patients who had implantation of a conventional pacemaker or an ICD or had a
revision of a pacemaker or other device leads within 1 month before starting treatment
with LCZ696 are excluded.

17. Heart transplant or ventricular assistance device (VAD) or intent to transplant (on
transplant list) or implant a VAD

18. History of severe pulmonary disease

19. Diagnosis of peripartum or chemotherapy induced cardiomyopathy within the 12 months
prior to starting treatment with LCZ696

20. Documented untreated ventricular arrhythmia with syncopal episodes within the 3 months
prior to starting treatment with LCZ696

21. Symptomatic bradycardia or second or third degree heart block without a pacemaker

22. Presence of hemodynamically significant mitral and/or aortic valve disease, except
mitral regurgitation secondary to left ventricular dilatation

23. Presence of other hemodynamically significant obstructive lesions of left ventricular
outflow tract, including aortic and sub-aortic stenosis

24. Any surgical or medical condition which might significantly alter the absorption,
distribution, metabolism, or excretion of study drugs, including but not limited to
any of the following:

- History of active inflammatory bowel disease during the 12 months before starting
treatment with LCZ696.

- Current duodenal or gastric ulcers during the 3 months prior to starting
treatment with LCZ696

- Evidence of hepatic disease as determined by any one of the following: AST or ALT
values exceeding 2 x ULN prior to starting treatment with LCZ696, history of
hepatic encephalopathy, history of esophageal varices, or history of portacaval
shunt

- Active treatment with cholestyramine or colestipol resins

25. Evidence of hepatic disease as determined by any one of the following: AST or ALT
values exceeding 3 x ULN prior to starting treatment with LCZ696, history of hepatic
encephalopathy, history of esophageal varices, or history of portacaval shunt

26. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
female after conception and until the termination of gestation, confirmed by a
positive hCG laboratory test (above 5 mIU/mL)

27. Women of child-bearing potential, defined as all women physiologically capable of
becoming pregnant, including women whose career, lifestyle, or sexual orientation
precludes intercourse with a male partner and women whose partners have been
sterilized by vasectomy or other means, UNLESS they are using two birth control
methods. The two methods can be a double barrier method (if accepted by the local
regulatory authority and ethics committee) or a barrier method plus a hormonal method

- Adequate barrier methods of contraception include: diaphragm, condom (by the
partner), intrauterine device (copper or hormonal), sponge or spermicide.
Hormonal contraceptives include any marketed contraceptive agent that includes an
estrogen and/or a progesterone agent.

- Reliable contraception should be maintained throughout the treatment and for 7
days after LCZ696 treatment discontinuation

- Women are considered post-menopausal and not of child bearing potential if they
have had 12 months of natural (spontaneous) amenorrhea with an appropriate
clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six
months of spontaneous amenorrhea, or have had surgical bilateral oophorectomy
(with or without hysterectomy) at least six weeks ago. In the case of
oophorectomy alone, only when the reproductive status of the woman has been
confirmed by follow up hormone level assessment.

28. Presence of any other disease with a life expectancy of < 3 years

29. Any condition, not identified in the protocol that in the opinion of the treating
physician is likely to prevent the patient from safely tolerating LCZ696 or complying
with the requirements of the therapy.

Study design
Purpose of the study
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
No longer available
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,WA
Recruitment hospital [1] 0 0
Novartis Investigative Site - Darlinghurst
Recruitment hospital [2] 0 0
Novartis Investigative Site - North Ryde
Recruitment hospital [3] 0 0
Novartis Investigative Site - Perth
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2109 - North Ryde
Recruitment postcode(s) [3] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
Austria
State/province [2] 0 0
Krems
Country [3] 0 0
Austria
State/province [3] 0 0
Salzburg
Country [4] 0 0
Austria
State/province [4] 0 0
St. Poelten
Country [5] 0 0
Austria
State/province [5] 0 0
Vienna
Country [6] 0 0
Austria
State/province [6] 0 0
Wien
Country [7] 0 0
Brazil
State/province [7] 0 0
BA
Country [8] 0 0
Brazil
State/province [8] 0 0
CE
Country [9] 0 0
Brazil
State/province [9] 0 0
MG
Country [10] 0 0
Brazil
State/province [10] 0 0
Rio Grande Do Sul
Country [11] 0 0
Brazil
State/province [11] 0 0
RS
Country [12] 0 0
Croatia
State/province [12] 0 0
HRV
Country [13] 0 0
Cyprus
State/province [13] 0 0
Limassol
Country [14] 0 0
Cyprus
State/province [14] 0 0
Nicosia
Country [15] 0 0
France
State/province [15] 0 0
Bouches Du Rhone
Country [16] 0 0
France
State/province [16] 0 0
Cedex
Country [17] 0 0
France
State/province [17] 0 0
France / La Reunion
Country [18] 0 0
France
State/province [18] 0 0
Amiens cedex 1
Country [19] 0 0
France
State/province [19] 0 0
Amilly
Country [20] 0 0
France
State/province [20] 0 0
Angers Cedex 9
Country [21] 0 0
France
State/province [21] 0 0
Antibes
Country [22] 0 0
France
State/province [22] 0 0
Aressy
Country [23] 0 0
France
State/province [23] 0 0
Avignon Cedex 2
Country [24] 0 0
France
State/province [24] 0 0
Avignon
Country [25] 0 0
France
State/province [25] 0 0
Bayeux
Country [26] 0 0
France
State/province [26] 0 0
Beziers Cedex
Country [27] 0 0
France
State/province [27] 0 0
Bobigny
Country [28] 0 0
France
State/province [28] 0 0
Brest Armees
Country [29] 0 0
France
State/province [29] 0 0
Brest
Country [30] 0 0
France
State/province [30] 0 0
Bron Cedex
Country [31] 0 0
France
State/province [31] 0 0
Bron
Country [32] 0 0
France
State/province [32] 0 0
Caen Cedex
Country [33] 0 0
France
State/province [33] 0 0
Caen
Country [34] 0 0
France
State/province [34] 0 0
Cambrai Cedex
Country [35] 0 0
France
State/province [35] 0 0
Cannes Cedex
Country [36] 0 0
France
State/province [36] 0 0
Chambéry cedex
Country [37] 0 0
France
State/province [37] 0 0
Chaumont Cedex
Country [38] 0 0
France
State/province [38] 0 0
Cherbourg Octeville
Country [39] 0 0
France
State/province [39] 0 0
Clamart
Country [40] 0 0
France
State/province [40] 0 0
Clermont-Ferrand cedex 1
Country [41] 0 0
France
State/province [41] 0 0
Compiègne cedex
Country [42] 0 0
France
State/province [42] 0 0
Contamine Sur Arve
Country [43] 0 0
France
State/province [43] 0 0
Corbeil Essonnes
Country [44] 0 0
France
State/province [44] 0 0
Cornebarrieu
Country [45] 0 0
France
State/province [45] 0 0
Dijon
Country [46] 0 0
France
State/province [46] 0 0
Eaubonne
Country [47] 0 0
France
State/province [47] 0 0
Honfleur Cedex
Country [48] 0 0
France
State/province [48] 0 0
Hyeres
Country [49] 0 0
France
State/province [49] 0 0
La Roche sur Yon Cedex
Country [50] 0 0
France
State/province [50] 0 0
La Seyne sur mer
Country [51] 0 0
France
State/province [51] 0 0
La Tronche
Country [52] 0 0
France
State/province [52] 0 0
Lille Cedex
Country [53] 0 0
France
State/province [53] 0 0
Limoges
Country [54] 0 0
France
State/province [54] 0 0
Lyon CEDEX 04
Country [55] 0 0
France
State/province [55] 0 0
Lyon
Country [56] 0 0
France
State/province [56] 0 0
Marseille Cedex 05
Country [57] 0 0
France
State/province [57] 0 0
Marseille Cedex 20
Country [58] 0 0
France
State/province [58] 0 0
Marseille
Country [59] 0 0
France
State/province [59] 0 0
Metz Cedex
Country [60] 0 0
France
State/province [60] 0 0
Metz-Tessy
Country [61] 0 0
France
State/province [61] 0 0
Monaco
Country [62] 0 0
France
State/province [62] 0 0
Montbeliard Cedex
Country [63] 0 0
France
State/province [63] 0 0
Montpellier Cedex
Country [64] 0 0
France
State/province [64] 0 0
Montpellier
Country [65] 0 0
France
State/province [65] 0 0
Morlaix Cedex
Country [66] 0 0
France
State/province [66] 0 0
Moulins Cedex
Country [67] 0 0
France
State/province [67] 0 0
Mulhouse Cedex
Country [68] 0 0
France
State/province [68] 0 0
Mâcon Cedex
Country [69] 0 0
France
State/province [69] 0 0
Nantes Cedex 1
Country [70] 0 0
France
State/province [70] 0 0
Neuilly-sur-seine
Country [71] 0 0
France
State/province [71] 0 0
Nice Cedex 1
Country [72] 0 0
France
State/province [72] 0 0
Nice Cedex 2
Country [73] 0 0
France
State/province [73] 0 0
Nimes
Country [74] 0 0
France
State/province [74] 0 0
Paris Cedex 10
Country [75] 0 0
France
State/province [75] 0 0
Paris Cedex 13
Country [76] 0 0
France
State/province [76] 0 0
Paris Cedex 14
Country [77] 0 0
France
State/province [77] 0 0
Pau Cedex
Country [78] 0 0
France
State/province [78] 0 0
Perpignan
Country [79] 0 0
France
State/province [79] 0 0
Pessac Cedex
Country [80] 0 0
France
State/province [80] 0 0
Poitiers
Country [81] 0 0
France
State/province [81] 0 0
Pont L'Abbe
Country [82] 0 0
France
State/province [82] 0 0
Pontarlier Cedex
Country [83] 0 0
France
State/province [83] 0 0
Pontoise
Country [84] 0 0
France
State/province [84] 0 0
Rennes Cedex 9
Country [85] 0 0
France
State/province [85] 0 0
Rouen Cedex
Country [86] 0 0
France
State/province [86] 0 0
Rumilly
Country [87] 0 0
France
State/province [87] 0 0
Saint Denis
Country [88] 0 0
France
State/province [88] 0 0
Saint Etienne Cedex 2
Country [89] 0 0
France
State/province [89] 0 0
Saint Palais
Country [90] 0 0
France
State/province [90] 0 0
Saint-Germain-en-Laye
Country [91] 0 0
France
State/province [91] 0 0
St Jean
Country [92] 0 0
France
State/province [92] 0 0
St. Etienne
Country [93] 0 0
France
State/province [93] 0 0
Strasbourg
Country [94] 0 0
France
State/province [94] 0 0
Thonon Les Bains Cedex
Country [95] 0 0
France
State/province [95] 0 0
Toulouse Cedex
Country [96] 0 0
France
State/province [96] 0 0
Toulouse
Country [97] 0 0
France
State/province [97] 0 0
Tours
Country [98] 0 0
France
State/province [98] 0 0
Valence Cedex 9
Country [99] 0 0
France
State/province [99] 0 0
Valenciennes Cedex
Country [100] 0 0
France
State/province [100] 0 0
Vandoeuvre Les Nancy
Country [101] 0 0
France
State/province [101] 0 0
Vichy
Country [102] 0 0
France
State/province [102] 0 0
Villefranche sur Saone
Country [103] 0 0
France
State/province [103] 0 0
Wattrelos
Country [104] 0 0
Germany
State/province [104] 0 0
OT Bartmannshagen
Country [105] 0 0
Germany
State/province [105] 0 0
Ahlen
Country [106] 0 0
Germany
State/province [106] 0 0
Augsburg
Country [107] 0 0
Germany
State/province [107] 0 0
Bad Endbach
Country [108] 0 0
Germany
State/province [108] 0 0
Bad Homburg
Country [109] 0 0
Germany
State/province [109] 0 0
Bad Kreuznach
Country [110] 0 0
Germany
State/province [110] 0 0
Bad Krozingen
Country [111] 0 0
Germany
State/province [111] 0 0
Bad Oeynhausen
Country [112] 0 0
Germany
State/province [112] 0 0
Berlin
Country [113] 0 0
Germany
State/province [113] 0 0
Bielefeld
Country [114] 0 0
Germany
State/province [114] 0 0
Bonn
Country [115] 0 0
Germany
State/province [115] 0 0
Chemnitz
Country [116] 0 0
Germany
State/province [116] 0 0
Cologne
Country [117] 0 0
Germany
State/province [117] 0 0
Dessau-Rosslau
Country [118] 0 0
Germany
State/province [118] 0 0
Diepholz
Country [119] 0 0
Germany
State/province [119] 0 0
Dinslaken
Country [120] 0 0
Germany
State/province [120] 0 0
Dortmund
Country [121] 0 0
Germany
State/province [121] 0 0
Dresden
Country [122] 0 0
Germany
State/province [122] 0 0
Dusseldorf
Country [123] 0 0
Germany
State/province [123] 0 0
Eilenburg
Country [124] 0 0
Germany
State/province [124] 0 0
Eschwege
Country [125] 0 0
Germany
State/province [125] 0 0
Essen
Country [126] 0 0
Germany
State/province [126] 0 0
Frankfurt
Country [127] 0 0
Germany
State/province [127] 0 0
Friedrichroda
Country [128] 0 0
Germany
State/province [128] 0 0
Goettingen
Country [129] 0 0
Germany
State/province [129] 0 0
Gronau
Country [130] 0 0
Germany
State/province [130] 0 0
Guenzburg
Country [131] 0 0
Germany
State/province [131] 0 0
Hamburg
Country [132] 0 0
Germany
State/province [132] 0 0
Hannover
Country [133] 0 0
Germany
State/province [133] 0 0
Hassfurt
Country [134] 0 0
Germany
State/province [134] 0 0
Hassloch
Country [135] 0 0
Germany
State/province [135] 0 0
Hohenstein-Ernstthal
Country [136] 0 0
Germany
State/province [136] 0 0
Jena
Country [137] 0 0
Germany
State/province [137] 0 0
Karlsruhe
Country [138] 0 0
Germany
State/province [138] 0 0
Kassel
Country [139] 0 0
Germany
State/province [139] 0 0
Koeln
Country [140] 0 0
Germany
State/province [140] 0 0
Köthen
Country [141] 0 0
Germany
State/province [141] 0 0
Lauchringen
Country [142] 0 0
Germany
State/province [142] 0 0
Leipzig
Country [143] 0 0
Germany
State/province [143] 0 0
Ludwigshafen
Country [144] 0 0
Germany
State/province [144] 0 0
Magdeburg
Country [145] 0 0
Germany
State/province [145] 0 0
Mainz
Country [146] 0 0
Germany
State/province [146] 0 0
Mannheim
Country [147] 0 0
Germany
State/province [147] 0 0
Marl
Country [148] 0 0
Germany
State/province [148] 0 0
Muenchen
Country [149] 0 0
Germany
State/province [149] 0 0
Munchen
Country [150] 0 0
Germany
State/province [150] 0 0
Munster
Country [151] 0 0
Germany
State/province [151] 0 0
Oldenburg
Country [152] 0 0
Germany
State/province [152] 0 0
Pressath
Country [153] 0 0
Germany
State/province [153] 0 0
Rostock
Country [154] 0 0
Germany
State/province [154] 0 0
Ulm
Country [155] 0 0
Germany
State/province [155] 0 0
Weinheim
Country [156] 0 0
Germany
State/province [156] 0 0
Wildeshausen
Country [157] 0 0
Germany
State/province [157] 0 0
Wolfratshausen
Country [158] 0 0
Germany
State/province [158] 0 0
Wuerzburg
Country [159] 0 0
Greece
State/province [159] 0 0
Evros
Country [160] 0 0
Greece
State/province [160] 0 0
GR
Country [161] 0 0
Greece
State/province [161] 0 0
Athens
Country [162] 0 0
Greece
State/province [162] 0 0
Chaidari
Country [163] 0 0
Greece
State/province [163] 0 0
Chios
Country [164] 0 0
Greece
State/province [164] 0 0
Edessa
Country [165] 0 0
Greece
State/province [165] 0 0
Elefsina
Country [166] 0 0
Greece
State/province [166] 0 0
Glyfada
Country [167] 0 0
Greece
State/province [167] 0 0
Heraklion - Crete
Country [168] 0 0
Greece
State/province [168] 0 0
Heraklion
Country [169] 0 0
Greece
State/province [169] 0 0
Ioannina
Country [170] 0 0
Greece
State/province [170] 0 0
Kalamata
Country [171] 0 0
Greece
State/province [171] 0 0
Karditsa
Country [172] 0 0
Greece
State/province [172] 0 0
Katerini
Country [173] 0 0
Greece
State/province [173] 0 0
Kavala
Country [174] 0 0
Greece
State/province [174] 0 0
Kerkyra
Country [175] 0 0
Greece
State/province [175] 0 0
Kilkis
Country [176] 0 0
Greece
State/province [176] 0 0
Kozani
Country [177] 0 0
Greece
State/province [177] 0 0
Maroussi
Country [178] 0 0
Greece
State/province [178] 0 0
Piraeus
Country [179] 0 0
Greece
State/province [179] 0 0
Rio Patra
Country [180] 0 0
Greece
State/province [180] 0 0
Thesaloniki
Country [181] 0 0
Greece
State/province [181] 0 0
Thessaloniki
Country [182] 0 0
Greece
State/province [182] 0 0
Volos
Country [183] 0 0
Ireland
State/province [183] 0 0
Co Dublin
Country [184] 0 0
Ireland
State/province [184] 0 0
Dublin
Country [185] 0 0
Lebanon
State/province [185] 0 0
Ashrafieh
Country [186] 0 0
Lebanon
State/province [186] 0 0
Beirut
Country [187] 0 0
Lebanon
State/province [187] 0 0
Saida
Country [188] 0 0
Lebanon
State/province [188] 0 0
Tripoli
Country [189] 0 0
Malta
State/province [189] 0 0
Msida
Country [190] 0 0
Panama
State/province [190] 0 0
Panama City
Country [191] 0 0
Panama
State/province [191] 0 0
Panama
Country [192] 0 0
Philippines
State/province [192] 0 0
Metro Manila
Country [193] 0 0
Philippines
State/province [193] 0 0
Makati City
Country [194] 0 0
Philippines
State/province [194] 0 0
Manila
Country [195] 0 0
Slovenia
State/province [195] 0 0
Ljubljana
Country [196] 0 0
Spain
State/province [196] 0 0
Andalucia
Country [197] 0 0
Spain
State/province [197] 0 0
Barcelona
Country [198] 0 0
Spain
State/province [198] 0 0
Cadiz
Country [199] 0 0
Spain
State/province [199] 0 0
Cantabria
Country [200] 0 0
Spain
State/province [200] 0 0
Cataluna
Country [201] 0 0
Spain
State/province [201] 0 0
Catalunya
Country [202] 0 0
Spain
State/province [202] 0 0
Cataluña
Country [203] 0 0
Spain
State/province [203] 0 0
Extremadura
Country [204] 0 0
Spain
State/province [204] 0 0
Galicia
Country [205] 0 0
Spain
State/province [205] 0 0
La Rioja
Country [206] 0 0
Spain
State/province [206] 0 0
Las Palmas De G.C
Country [207] 0 0
Spain
State/province [207] 0 0
Madrid
Country [208] 0 0
Spain
State/province [208] 0 0
Malaga
Country [209] 0 0
Spain
State/province [209] 0 0
Navarra
Country [210] 0 0
Spain
State/province [210] 0 0
Pais Vasco
Country [211] 0 0
Spain
State/province [211] 0 0
Badalona
Country [212] 0 0
Spain
State/province [212] 0 0
Baleares
Country [213] 0 0
Spain
State/province [213] 0 0
El Palmar (Murcia)
Country [214] 0 0
Spain
State/province [214] 0 0
Las Palmas de Gran Canaria
Country [215] 0 0
Spain
State/province [215] 0 0
Salamanca
Country [216] 0 0
Spain
State/province [216] 0 0
Sevilla
Country [217] 0 0
Spain
State/province [217] 0 0
Zaragoza
Country [218] 0 0
Switzerland
State/province [218] 0 0
LU
Country [219] 0 0
United Arab Emirates
State/province [219] 0 0
Abu Dhabi
Country [220] 0 0
United Arab Emirates
State/province [220] 0 0
Ras Al Khaimah

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Novartis has set up this global Multiple Patient Program (MPP) treatment plan to provide
access to life-saving treatment with LCZ696 for patients that were not previously exposed to
LCZ696 but have no other option to receive LCZ696 in their country prior to market
authorization OR commercial availability, based on local regulatory and legal requirements.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02389933
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02389933